Quick Summary
Hijiki (Sargassum fusiforme) is a brown seaweed traditionally used in East Asian cuisine and medicine. It contains bioactive compounds such as polysaccharides, phlorotannins, fucoidan, polyphenols, carotenoids, and fibers. These compounds have been primarily studied in preclinical research, suggesting diverse potential health effects including antioxidant, anti-inflammatory, antidiabetic, anticancer, immunomodulatory, and neuroprotective activities. Clinical evidence specific to hijiki is limited and mostly indirect. Safety concerns have been raised relating to its inorganic arsenic content.
What is it
Hijiki is a type of brown macroalgae (Sargassum fusiforme) harvested mainly in East Asia. It has a long history of use as a food ingredient and traditional medicine. The seaweed is rich in nutrients and various bioactive substances thought to contribute to health benefits.
Traditional Uses
- Used in East Asian cooking, often as a side dish or ingredient in soups and salads.
- Employed traditionally to support general health and digestive function.
- Utilized in folk medicine for its presumed detoxifying and strengthening effects.
Active Compounds
- Polysaccharides: Including fucoidan, known for biological activities in various studies.
- Phlorotannins: Polyphenols with antioxidant and anti-inflammatory potential.
- Polyphenols and Carotenoids: Contribute to antioxidant effects.
- Dietary Fibers: Important for digestive health and metabolic modulation.
Potential Benefits with Evidence Levels
- Antioxidant and Anti-inflammatory Effects
Evidence Level: Preclinical and in vitro
Phlorotannins and other polyphenols from hijiki have shown antioxidant and anti-neuroinflammatory activities in lab and animal studies, suggesting possible applications in functional foods and neuroprotection (He et al., 2026; Pereira & Valado, 2026). - Metabolic Syndrome and Glycemic Control
Evidence Level: Limited human clinical and preclinical evidence
Compounds from brown seaweeds, including hijiki, may modulate gut microbiota and support glucose and lipid metabolism. Some clinical trials on edible algae report modest blood pressure and lipid-lowering effects, though specific evidence for hijiki is not well established (Fan et al., 2026; Casas-Agustench et al., 2025; Zang et al., 2023). - Antitumor and Immunomodulatory Activities
Evidence Level: Preclinical and some clinical supportive evidence (mostly for fucoidan)
Fucoidan polysaccharides extracted from brown seaweed show antitumor, anti-inflammatory, and immunomodulating effects in animal models and early clinical contexts. Direct evidence from hijiki-specific polysaccharides is limited (Kiselevskiy et al., 2022; Cao et al., 2021). - Neuroprotective Potential
Evidence Level: Preclinical
Seaweed-derived compounds such as fucoxanthin and phlorotannins have shown antioxidant and neuroprotective effects in preclinical models of neurodegenerative diseases. However, confirmation in human studies is lacking (Ward et al., 2025; Pereira & Valado, 2026). - Nutritional Value and Functional Food Ingredient
Evidence Level: Descriptive and compositional data
Hijiki contains protein, dietary fiber, vitamins, minerals, and polysaccharides which contribute to its nutritional and potential functional food benefits. Composition can vary depending on environment and processing methods (Meinita et al., 2021; Zhang et al., 2025).
Side Effects
No severe adverse effects specifically attributed to hijiki intake have been reported in clinical literature. However, hijiki is known to contain inorganic arsenic, which poses a toxicity risk. There is limited safety data overall regarding hijiki consumption.
Drug Interactions
Currently, no specific clinical data exist on drug interactions with hijiki in the scientific literature.
Who Should Avoid It
Due to potential inorganic arsenic contamination, hijiki consumption is contraindicated or advised against in populations at risk of arsenic exposure. This includes individuals with high baseline arsenic exposure or compromised detoxification abilities. Additionally, caution is advised in pregnant or breastfeeding women due to lack of safety data and possible heavy metal contamination.
Evidence Limitations
Most evidence for hijiki’s effects derives from in vitro and animal studies or indirect clinical studies involving brown seaweeds in general rather than hijiki specifically. Clinical trials focused on hijiki are few and often of limited quality. Variability in bioactive compounds among different seaweed species and preparations complicates extrapolating findings. Furthermore, unresolved safety concerns related to inorganic arsenic contamination limit clinical recommendations and wider dietary use.
References
- Fan Y, Gong S, Wang X. Traditional Chinese medicine in diabetes management: a comprehensive review of mechanisms and therapeutic potential. Front Endocrinol. 2026.
- Can B, Sanlier N. Secret heroes of the sea: brown macroalgae and their bioactive powers-a narrative review. Front Nutr. 2026.
- He W, Kong Q, Li H, et al. Ultrasonic-assisted extraction, purification, identification, and bioactivity evaluation of phlorotannins from Sargassum fusiforme. Ultrason Sonochem. 2026.
- Ward K, Cole MH, Griffiths LR, et al. Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer’s Disease. Molecules. 2025.
- Casas-Agustench P, Mínguez S, Brookes Z, Bescos R. Edible Algae Reduce Blood Pressure in Humans: A Systematic Review and Meta-Analysis. J Hum Nutr Diet. 2025.
- Zang L, Baharlooeian M, Terasawa M, et al. Beneficial effects of seaweed-derived components on metabolic syndrome via gut microbiota modulation. Front Nutr. 2023.
- Kiselevskiy MV, Anisimova NY, Ustyuzhanina NE, et al. Perspectives for the Use of Fucoidans in Clinical Oncology. Int J Mol Sci. 2022.
- Cao LM, Sun ZX, Makale EC, et al. Antitumor activity of fucoidan: a systematic review and meta-analysis. Transl Cancer Res. 2021.
- Meinita MDN, Harwanto D, Sohn JH, et al. Hizikia fusiformis: Pharmacological and Nutritional Properties. Foods. 2021.
- EFSA Panel on Contaminants in the Food Chain (CONTAM). Update of the risk assessment of inorganic arsenic in food. EFSA J. 2024.
- Toxicity of so-called edible hijiki seaweed (Sargassum fusiforme) containing inorganic arsenic. Regul Toxicol Pharmacol. 2012.
Last Reviewed
June 2024
Disclaimer: This page is for informational purposes only and does not constitute medical advice. The use of hijiki or any herbal product should be discussed with a qualified healthcare provider, especially in the presence of health conditions or when taking medications. Safety concerns related to inorganic arsenic contamination in hijiki should be carefully considered.